Angiotech Pharmaceuticals’ Recapitalization
|Areas||Banking and Finance Law, Corporate Finance and Securities, Corporate Restructuring, Environmental Law, Intellectual Property , Litigation, Tax|
Goodmans represented the Ad Hoc Committee of Noteholders of Angiotech Pharmaceuticals, Inc. ("Angiotech") in connection with Angiotech's successful implementation of the second amended and restated plan of compromise or arrangement under the Companies’ Creditors Arrangement Act ("CCAA") as approved by the Supreme Court of British Columbia on April 6, 2011. Pursuant to the plan, the US$250 million 7.75% senior subordinated notes due 2014 (the “Subordinated Notes”) were cancelled and eliminated in exchange for the issuance of new common shares of Angiotech to the holders of such Subordinated Notes.
Through an exchange offer, the US$325 million floating rate notes due 2013 were effectively reinstated subject to certain limited amendments.
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. Angiotech had 1400 employees and was publicly traded in Canada prior to its recapitalization.